BioSupply Trends Quarterly logo
Search
Close this search box.
Winter 2020 - Integrated Care

Octapharma Introduces New SCIG Product and IgCares Program

At the Immune Deficiency Foundation (IDF) National Conference in June, Octapharma introduced its newest product, Cutaquig (immune globulin subcutaneous [human] 16.5% solution) for subcutaneous infusion indicated for treatment of primary humoral immunodeficiency (PI) in adults.

At the Immune Deficiency Foundation (IDF) National Conference in June, Octapharma introduced its newest product, Cutaquig (immune globulin subcutaneous [human] 16.5% solution) for subcutaneous infusion indicated for treatment of primary humoral immunodeficiency (PI) in adults. The company also launched its free IgCares program, an initiative managed through the community portal at www.IgCares.com providing a safety and sustainability service that transforms medical waste into energy; Octapharma donations to PI nonprofit organizations; access to educational and informational resources for PI patients; and personal connections to peers, the PI community and patient advocates. “Multiple clinical trials have demonstrated the safety and efficacy of Cutaquig in treating PI in adults, so we are pleased to introduce the product,” said Octapharma USA President Flemming Nielsen. “We are excited to launch IgCares as well because it provides Cutaquig patients with benefits through educational and community resources, as well as support for patient organizations and the environment.”

IgCares enables patients to return product materials at no cost, keeping their medical waste out of landfills. With each monthly shipment of Cutaquig, patients will receive a custom sharps container for needles and other medical waste and an additional box for product shipping materials. “The IgCares initiative helps protect the environment by transforming medical waste into energy,” added Nielsen. “Everything patients return will be repurposed into an industrial material used to generate electricity for homes and businesses.”

The IgCares initiative also lets patients access educational and informational resources, including a wide range of tips, tactics and tools to succeed in the patient treatment journey. Its portal also connects patients with peers, the PI community and patient advocates who are available to answer questions. Patients earn points through IgCares every time they fill a prescription, complete educational activities, track their treatment and participate in the sustainability program. They can convert their points into a charitable donation by Octapharma made to one of four PI community organizations, including IDF, the Jeffrey Modell Foundation, the Foundation for Primary Immunodeficiency Diseases and the International Patient Organisation for Primary Immunodeficiencies.

Cutaquig is available through four distribution partners: Nufactor, Healix, KabaFusion and Main Bridge Health Partners.

References

Octapharma Introduces Cutaquig & IgCares, Sponsors IDF National Conference. BusinessWire, June 27, 2019. Accessed at finance.yahoo.com/news/octapharma-introduces-cutaquig-igcares-sponsors-153500478.html.

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.